Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 9c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $74.52 +0.15%
EPS Growth %: +4.8%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +4.8%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $45.89 million versus the consensus estimate of $37.52 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
